Sign in

    Jennifer Teubl

    Research Associate at Robert W. Baird & Co.

    Jennifer Rose Teubl is a Research Associate at Robert W. Baird & Co., specializing in equity research with a focus on the biotechnology and life sciences sectors. She has covered companies such as Arbutus Biopharma Corp, providing detailed earnings call analyses and industry insights that support investment decisions. Teubl began her analyst career prior to 2020 and has contributed to Baird’s research division since at least that time, following earlier scientific research roles linked to proteomics and forensic applications. She holds advanced academic credentials, reflected by her PhD, and is presumed to maintain standard professional securities licenses for her analyst position.

    Jennifer Teubl's questions to InflaRx (IFRX) leadership

    Jennifer Teubl's questions to InflaRx (IFRX) leadership • Q3 2019

    Question

    Jennifer Teubl from Robert W. Baird & Co. asked about the potential timing of a future trial, should regulators give a go-ahead, and requested more granular detail on how many patients in the nonresponder group received a different dosing schedule in the open-label extension compared to the main trial period.

    Answer

    Executive Niels Riedemann explained that it is too early to speculate on the timing or design of a future study, as it depends on the outcome of regulatory discussions planned in the coming months. He clarified that the nonresponder group (84 patients) and responder group (72 patients) were composed of roughly 14-17 patients from each of the original five treatment arms, noting these small subgroups require cautious interpretation due to high variability.

    Ask Fintool Equity Research AI